

Yevgeniy Khariton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2019591/publications.pdf>

Version: 2024-02-01

21
papers

1,029
citations

759233

12
h-index

839539

18
g-index

23
all docs

23
docs citations

23
times ranked

1425
citing authors

#	ARTICLE	IF	CITATIONS
1	Use Of Implantable Pulmonary Artery Pressure Monitoring To Guide Care Of Patients With Ambulatory Heart Failure; The First Three Years In A Real World, Single Center Experience. Journal of Cardiac Failure, 2022, 28, S42.	1.7	0
2	Heterogeneity of health status treatment response with sacubitril/valsartan: insights from the CHAMPaCHF registry. ESC Heart Failure, 2021, 8, 710-713.	3.1	3
3	Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the <scp>DEFINEaCHF</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 1426-1430.	4.4	14
4	Association between sacubitril/valsartan initiation and realaeworld health status trajectories over 18Amoents in heart failure with reduced ejection fraction. ESC Heart Failure, 2021, 8, 2670-2678.	3.1	7
5	Association Between Change in Ambulatory Hemodynamic Pressures and Symptoms of Heart Failure. Circulation: Heart Failure, 2021, 14, e008446.	3.9	5
6	The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nature Medicine, 2021, 27, 1954-1960.	30.7	299
7	Systemizing the Evaluation of Acute Heart Failure in the Emergency Department. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006168.	2.2	7
8	Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes inAHeartAFailure With Reduced EjectionAFraction. JACC: Heart Failure, 2019, 7, 933-941.	4.1	31
9	Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction. Circulation, 2019, 140, 1463-1476.	1.6	279
10	Association of Changes in HeartAFailure Treatment With Patientsa™ Health Status. JACC: Heart Failure, 2019, 7, 615-625.	4.1	20
11	Target Doses of Heart Failure MedicalAThery and Blood Pressure. JACC: Heart Failure, 2019, 7, 350-358.	4.1	67
12	Health Status Variation Across Practices in Outpatients With Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004668.	2.2	15
13	Association Between Prompt Defibrillation and Epinephrine Treatment With Long-Term Survival After In-Hospital Cardiac Arrest. Circulation, 2018, 137, 2041-2051.	1.6	27
14	Health Status Benefits of SuccessfulAChronic Total Occlusion Revascularization Across the SpectrumAofALeft Ventricular Function. JACC: Cardiovascular Interventions, 2018, 11, 2276-2283.	2.9	11
15	Guidelineadirected statin intensification in patients with new or worsening symptoms of peripheral artery disease. Clinical Cardiology, 2018, 41, 1414-1422.	1.8	5
16	Health Status Disparities by Sex, Race/Ethnicity,Aand Socioeconomic Status in Outpatients With Heart Failure. JACC: Heart Failure, 2018, 6, 465-473.	4.1	65
17	Vaccination Trends in Patients With HeartAFailure. JACC: Heart Failure, 2018, 6, 844-855.	4.1	30
18	CURRENT MORE IMPORTANT THAN PAST: INTERPRETING SERIAL HEART FAILURE SPECIFIC HEALTH STATUS IN HEART FAILURE PATIENTS WITH REDUCED EJECTION FRACTION. Journal of the American College of Cardiology, 2017, 69, 910.	2.8	0

#	ARTICLE	IF	CITATIONS
19	HEALTH STATUS BENEFITS OF SUCCESSFUL CHRONIC TOTAL OCCLUSION PCI IN PATIENTS WITH DEPRESSED LEFT VENTRICULAR SYSTOLIC FUNCTION: INSIGHTS FROM THE OPEN-CTO REGISTRY. Journal of the American College of Cardiology, 2017, 69, 1326.	2.8	1
20	Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments With Death and Hospitalization in Patients With Heart Failure With Preserved and Reduced Ejection Fraction. JAMA Cardiology, 2017, 2, 1315.	6.1	126
21	Impact of Transesophageal Echocardiography on Management in Patients With Suspected Cardioembolic Stroke. American Journal of Cardiology, 2014, 114, 1912-1916.	1.6	17